

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72279 A2

- (51) International Patent Classification⁷: **A61K 9/00** (74) Agent: TULLETT, Rodney, C.; Christensen O'Connor Johnson & Kindness PLLC, Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).
- (21) International Application Number: PCT/US01/09405
- (22) International Filing Date: 23 March 2001 (23.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/534,056 24 March 2000 (24.03.2000) US
- (71) Applicants: **BOSTON SCIENTIFIC LIMITED** [IE/BB]; The Corporate Center, Bush Hill, Bay Street, St. Michael (BB). **FRESENIUS KABI AB** [SE/SE]; S-751 74 Uppsala (SE).
- (72) Inventors: **LYONS, Robert, T.**; 27164 Woodbluff Road, Laguna Hills, CA 92653 (US). **DILLARD, David, H.**; 7923-152nd Avenue NE, Redmond, WA 98052 (US). **FIEGGEN, Bruce**; 41 Coventry Road, Wayne, NJ 07470 (US). **RAUKER, Robert, M.**; 23 Dearth Circle, Ashland, MA 01721 (US). **BLUNI, Scott, T.**; 163 Mossman Road, Sudbury, MA 01776 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/72279 A2

(54) Title: MEDICAL EMULSION FOR LUBRICATION AND DELIVERY OF DRUGS

(57) Abstract: A medical lubricant suitable for injection into the blood stream of a patient. The lubricant is suitable for use with rotating equipment such as atherectomy drive shafts moving within sheaths and over guide wires and other minimally invasive medical devices introduced into a patient through a catheter like instrument. The lubricant is an oil-in-water emulsion including a surfactant, a co-surfactant, and a pH buffer. The lubricant can further include a cryogenic agent and a pH adjusting agent. One lubricant includes olive oil as an emulsified oil, egg yolk phospholipid as a surfactant, sodium deoxycholate as a co-surfactant, glycerin as a cryogenic agent, L-histidine as a pH buffer, and is pH adjusted using sodium hydroxide. The lubricant can also include a therapeutic agent. The lubricant can withstand freeze/thaw cycles as well as saline dilution, heating, and shear stress without significant creaming, separation, or unacceptable increases in oil droplet size. Compared to saline, the lubricant provides significantly increased lubrication efficiency for rapidly moving parts.

MEDICAL EMULSION FOR LUBRICATION AND DELIVERY OF DRUGS
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Application No. 08/935,698, filed September 23, 1997, U.S. Patent No. ____.

Field of the Invention

This invention relates to a lubricating composition for use with biomedical devices. More particularly, this invention relates to an injectable emulsion capable of being used within human arteries during a rotational atherectomy procedure that both lubricates the atherectomy device and is capable of acting as a drug carrier.

Background of the Invention

It is well known that, for various reasons, humans can develop a condition in which a type of plaque or hard deposit builds up along the walls of the blood vessels, thereby partially blocking the blood flow and causing severe medical conditions. Several different procedures have been developed for dealing with this situation.

One such procedure is rotational atherectomy, in which a rotary mechanical system removes relatively hard intravascular deposits from the walls of human arteries by differentially cutting away the inelastic, hardened deposits while sparing the soft, elastic tissue of the inner lining of the human blood vessels. The seminal patent that discloses a device for performing this procedure is U.S. Patent No. 4,990,134 (Auth) entitled "TRANSLUMINAL MICRODISSECTION DEVICE", the disclosure of which is incorporated herein by reference.

In the commercially available device described in U.S. Patent No. 4,990,134, known as the Rotablator®, an ellipsoidal burr coated with tiny diamond chips is rotated at a speed of at least approximately 155,000 revolutions per minute. The burr is connected to a drive motor capable of high speed rotation via a hollow, flexible,

helically-wound drive shaft, and is routed through the blood vessel over a narrow guide wire that extends through the central bore of the burr and its drive shaft. When this device is operated, the burr preferentially cuts hard, inelastic material (plaque) while sparing soft, elastic material (tissue) and generates microscopic debris fragments that are sufficiently small in size so as to pass through even the narrowest vascular channels (capillary beds) without clogging them.

This Rotablator® atherectomy device, as well as any other microdissection device that involves rotational ablation, necessarily generates thermal energy during its rotation. For this reason, as disclosed in U.S. Patent No. 4,990,134, a biocompatible saline solution is infused through a plastic sheath within which the drive shaft rotates, to cool the sliding interface during operation.

In addition to performing a cooling function, some lubrication is needed to prevent wear caused by rotational friction between the guide wire and the drive shaft or between the drive shaft and the plastic sheath. The major factors that affect wear in this type of rotational contact are load, temperature, surface speed, surface finish, surface hardness, contact area, time, and the type, amount and viscosity of the lubricant.

During extended operation of the device, however, additional lubrication should be provided to sustain the performance of the guide wire, the drive shaft and the sheath. Such a lubricant, if infused through the device from outside the patient's body, must of course, be non-toxic and safe for arterial use. In addition, to be effective in use with the Rotablator® advancer/guide wire system, the lubricant should be able to withstand shear stresses at 50°C and should not promote the agglomeration of ablated plaque particles.

Injectable oil-in-water emulsions are currently being used for two clinical applications. The first is for parenteral or intravenous nutrition, as a source of fat calories and essential fatty acids. Examples include Intralipid®, available from Pharmacia and Upjohn and Liposyn®, available from Abbott Laboratories. Emulsions are also being used as a vehicle for poorly water-soluble lipophilic drugs that cannot be injected directly. Examples include Diprivan®, containing the anesthetic drug propofol, and Diazemuls®, containing the drug diazepam.

Lipid emulsions are inherently unstable. No commercially available lipid emulsion is stable following dilution in physiological (0.9% w/v) salt solution. This instability is manifested by formation of large droplets of non-emulsified oil on the surface as well as by a shift in droplet size distribution towards much larger diameters. Such changes often occur within the first hour following dilution in saline

and are accelerated by heating or by applying any shear force. The relatively low pH and high ionic strength of saline contributes to this effect.

Commercial lipid emulsions separate into oil and water layers upon thawing after storage at freezing temperatures. For this reason, special care must be taken
5 when shipping in winter through geographic areas having below freezing temperatures. It is preferred that the lubricant be an emulsion which is stable in saline and stable upon freezing with subsequent thawing. The present invention meets these needs and overcomes other deficiencies in the prior art.

What would be desirable is an improved, pharmacologically compatible
10 medical lubricant that is capable of delivering therapeutic agents to target locations within the body. What has not been provided in the prior art is an injectable medical lubricant suitable for lubricating rotating and otherwise moving medical devices, where the lubricant can optionally act as a carrier for therapeutic agents to thereby yield a therapeutic effect to a treatment site in the body.

15 Summary of the Invention

The present invention includes a medical lubricant suitable for injection into a patient. The lubricant is an oil-in-water emulsion including an oil, a surfactant, a co-surfactant and water. The lubricant preferably also includes a cryogenic agent, a pH buffer, and a preservative. The lipid emulsion preferably has a mean particle or
20 droplet diameter of less than 1 micrometer, most preferably less than about 0.5 micrometer. The lubricant can be subjected to substantial shear by a rotating member, exhibits a commercially acceptable shelf life during storage under ambient temperatures, and is able to withstand freeze-thaw cycles without substantial degradation. The lubricant can be diluted in physiological saline for injection and
25 maintains suitable emulsion droplet size after such dilution.

The oil can be a vegetable oil or a medium chain triglyceride. The preferred oil is refined olive oil, which preferably comprises mostly mono-unsaturated oleic acid. The oil can lubricate medical devices such as rotating drive shafts in
atherectomy devices, thereby reducing wear on moving parts. A mean droplet size of
30 less than about 1 micrometer allows injection into the bloodstream and subsequent absorption by the body without ill effect. The emulsion most preferably includes about 20 g refined olive oil per 100 mL emulsion.

The surfactant can be a phospholipid, preferably purified egg yolk phospholipids. The surfactant stabilizes the oil droplets dispersed in the continuous
35 aqueous phase. The present invention preferably includes about 1.2 g egg yolk phospholipids per 100 mL emulsion.

The co-surfactant can be a salt of a bile acid, most preferably sodium deoxycholate. The co-surfactant significantly improves droplet stability after saline dilution, heating, and exposure to high shear forces. Droplet stability includes the resistance to formation of larger droplets, creaming, and formation of a separate oil layer. Bile salt, acting in conjunction with glycerin, provides improved freeze-thaw stability. Applicants believe the bile salt also improves lubricity by acting as a wetting agent, improving the coating of moving metal parts. The present invention most preferably includes about 0.4 g bile salt per 100 mL emulsion.

The cryogenic agent can be refined propylene glycol or glycerin, preferably glycerin. Glycerin also provides improved lubricity. The present invention preferably includes about 10 g glycerin per 100 mL emulsion.

The pH buffer imparts improved droplet stability in a saline diluent. Any physiological pH buffer may be used. When the pH buffer is an amino acid buffer said amino acid buffer usually has a concentration of less than 0.20 g/100 mL emulsion. The amino acid buffer is most preferably L-histidine in a concentration of about 0.16 g per 100 mL emulsion.

The preservative is preferably a heavy metal chelator such as disodium EDTA. EDTA, and the histidine buffer, serve as antioxidants, protecting unsaturated fatty acids found in egg yolk phospholipids. The antioxidants provide an extended shelf life for the emulsion at room temperature and inhibit peroxide formation during clinical use. Disodium EDTA is preferably present in about 0.014 g per 100 mL emulsion.

The emulsion preferably has the pH adjusted to between about 8.3 and 8.8 with a base such as sodium hydroxide. This pH range optimizes the emulsion stability in the presence of non-buffered saline, which is slightly acidic. Sodium hydroxide can be present in about 3.0 mEq per liter of emulsion.

An emulsion according to the present invention can be prepared by combining refined olive oil, 1.2% egg yolk phospholipid, 0.16% L-histidine (10 mM), 0.014% disodium EDTA (0.5 mM), and water, followed by ultrasonic processing for about 15 minutes. The emulsion can also be prepared using high pressure homogenization techniques well known to those skilled in the art.

In use, the emulsion can be stored for at least eighteen (18) months, preferably twenty-four (24) months at room temperature. The emulsion can be stored frozen at -30°C, and then thawed without causing significant changes in droplet size distribution. The emulsion can be added to normal, unbuffered 0.9% saline solution. One anticipated use is injection of the emulsion into an IV bag of saline, thereby

diluting the emulsion. The diluted emulsion can be infused from the IV bag through a catheter tube housing a rotating member such as an atherectomy drive shaft or an ultrasonic probe drive shaft. The emulsion serves to lubricate the moving parts and can thereafter enter the blood stream of a patient without ill effect.

- 5 In certain embodiments of the invention, the above described medical lubricant additionally includes one or more therapeutic agents to thereby provide a therapeutic effect to a treatment site in the body. One or more of the therapeutic agents may include a genetic material encoding a therapeutic agent, a non-genetic therapeutic material, proteins or cells that produce a therapeutic effect. The choice of
10 therapeutic agent will depend on the application. In one embodiment where the lubricant is used in conjunction with an atherectomy device, one or more of the therapeutic agents inhibits cell proliferation and provides an anti-restenosis effect. In other embodiments where the lubricant is used in conjunction with a transmyocardial revascularization (TMR) device or percutaneous myocardial revascularization (PMR)
15 device, one or more of the therapeutic agents promotes angiogenesis.

- In yet another aspect of the invention, a method is provided for lubricating an intravascular device. The inventive method involves first preparing a patient for a medical procedure and then inserting into the patient a medical device that is in need of lubrication. A medical oil emulsion lubricant is infused into the patient during the
20 insertion and/or operation of the medical device. The medical oil emulsion lubricant contains olive oil, an egg yolk phospholipid, a bile salt, an amino acid buffer and a desired therapeutic agent. In one embodiment of the method the medical procedure is atherectomy and the medical device is an intravascular device that is capable of differentially removing intravascular deposits from the walls of an artery. During the
25 atherectomy procedure the therapeutic agent present in the medical oil emulsion lubricant usually contains a cell proliferation inhibitor that provides an anti-restenosis effect. In another embodiment of the lubrication method, the medical procedure is myocardial revascularization and the medical device is a myocardial revascularization device. During the myocardial revascularization procedure it is
30 usual to include in the medical lubricant a therapeutic agent that promotes angiogenesis.

Detailed Description

- In a preferred embodiment of the invention, the oil-in-water emulsion lubricant comprises a mixture of water, oil, a surfactant, a co-surfactant, a
35 phospholipid, a cryogenic agent, a pH buffer and a preservative.

Preferably the oil used in the lipid emulsion lubricant is a liquid at room temperature, most preferably olive oil.

Chemically, olive oil contains mostly mono-unsaturated oleic acid. Different oil bases, such as either soybean oil, which contains a mixture of polyunsaturated fatty acids, mainly C₁₄, C₁₆, and C₁₈, or medium chain triglycerides (MCT) may also be used, especially with varying concentrations of the other ingredients and with different surfactants. Almond oil, coconut oil, corn oil, cotton seed oil, marine oil, palm kernel oil, peanut oil, safflower oil, sesame oil, sunflower oil, and physical or interesterified mixtures thereof can also be used. These other oil bases, however, are not as effective as olive oil. Quite surprisingly, we found that olive oil emulsions lubricate better than soybean oil emulsions. The lubricant reduces wear on moving components. In a preferred embodiment of the invention, the concentration of olive oil in the lubricant is from about 5 to about 40 g/100 mL emulsion, more preferably about 15 to about 25 g/100 mL emulsion, and is most preferably about 20 g/100 mL emulsion.

An emulsion is a dispersion of one immiscible liquid within another, commonly oil-in-water. An emulsifier is a surface active agent designed to coat and stabilize the dispersed droplets against coalescence. However, in certain formulations, this dispersion is insufficiently stabilized by the primary emulsifier which is typically added at concentrations of about 1-5% w/v. In such cases, a second surface active agent, known as a co-surfactant, may be added. A co-surfactant is typically used at a fractional concentration of the primary emulsifier, e.g., 0.1-1.0%. In principle, co-surfactants are added to accomplish specific tasks such as enhancing electrostatic surface charge on the dispersed droplets or strengthening the interfacial film between oil and water. In reality, it is quite difficult to predict in advance which co-surfactant, if any, will stabilize a novel emulsion formulation under specific environmental conditions.

A primary emulsifier in the lipid emulsion lubricant could, for example, be selected from a group of phospholipids such as soy bean or egg yolk phospholipids. A preferred phospholipid is egg yolk phospholipid, preferably present in a concentration of about 0.3 to about 3 g/100 mL emulsion, more preferably about 0.6 to about 1.8 g/100 mL emulsion, most preferably about 1.2 g/100 mL emulsion.

The co-surfactant could be, for example, PEG-400 (polyethylene glycol), Pluronic F68 (a nonionic, polyoxethylene-polyoxypropylene block copolymer, BASF), dimyristyl phosphatidyl glycerin (DMPG), or the salt of a bile acid. When PEG-400 is used, it can be present at about 5% weight/volume. When Pluronic F68

is used, it can be present at about 1% weight/volume. Preferably, the co-surfactant is the salt of a bile acid such as cholic acid, deoxycholic acid, taurocholic acid or mixtures thereof. Most preferably, the co-surfactant is sodium deoxycholate, as it is somewhat more effective in reducing wear than DMPG. In the present invention, the superiority of sodium deoxycholate over other tested co-surfactants was unexpected and unpredicted. In a preferred embodiment, sodium deoxycholate is present at a concentration of about 0.04 to about 4 g/100 mL emulsion more preferably about 0.2 to about 0.8 g/100 mL emulsion, most preferably about 0.4 g/100 mL emulsion.

A preferred cryogenic agent is refined propylene glycol or glycerin, most preferably glycerin. Glycerin serves to provide freeze tolerance and improves the overall lubricating properties of the emulsion. Glycerin is preferably present at a concentration of about 1 to about 30 g/100 mL emulsion, more preferably about 2 to about 20 g/100 mL emulsion, most preferably about 10 g/100 mL emulsion.

A preferred pH buffer is an amino acid buffer, for example, alanine, aspartic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, valine or mixtures thereof. Often the amino acid buffer is present at a concentration lower than about 0.20 g/100 mL. A preferred amino acid buffer is histidine. Histidine contributes significant pH buffering capacity in the critical pH 6 to 8 range, having a pK_a of about 6.0. This pH buffering contributes to emulsion stability after dilution in saline. In addition, histidine serves as an antioxidant, specifically a hydroxy radical scavenger. Histidine is preferably present at a concentration of about 0.01 to about 1 g/100 mL emulsion, more preferably about 0.05 to about 0.3 g/100 mL emulsion, most preferably about 0.16 g/100 mL emulsion.

A preferred preservative is a heavy metal chelator such as disodium EDTA. The combination of EDTA and histidine serves as a potent antioxidant to protect unsaturated fatty acids found in egg yolk phospholipids. This antioxidant system serves both to protect the emulsion in the bottle during prolonged storage at room temperature as well as to inhibit peroxide formation during clinical use. Disodium EDTA is preferably present at a concentration of about 0.001 to about 0.1 g/100 mL emulsion, more preferably about 0.01 to about 0.05 g/100 mL emulsion, most preferably about 0.014 g/100 mL emulsion.

Finally, sodium hydroxide can be added to titrate the emulsion to a final pH of about 8.3 to about 8.8. This pH range is chosen to optimize emulsion stability in the presence of non-buffered saline which is slightly acidic.

In order to manufacture the present invention, a mixture of water-for-injection with the ingredients listed above in the amounts described can be passed through a high pressure homogenizer. The resulting mixture is an opaque white, milky liquid that is a suspension of small oil droplets in water, with a normal droplet size distribution. The droplet size has a mean of about $0.4\ \mu\text{m}$ and a maximum of about $4\ \mu\text{m}$. The distribution includes 90% of droplets less than about $0.65\ \mu\text{m}$ and less than 0.5% of droplets greater than $1\ \mu\text{m}$. Even after experiencing high shear, all droplets remain less than about $5\ \mu\text{m}$.

The lubricant is to be shipped in sterile vials and injected into a sterile saline intravenous (IV) bag prior to use. During a rotational atherectomy procedure, the lubricant can be infused through the catheter of a Rotablator® system and then into the coronary artery. Because the present invention is safe for parenteral use, it is a potential lubricant for any device operating inside the human body. Examples of this are: interoperative milk into which endoscopic equipment is dipped before placement into the human body; coating for sutures in order to reduce friction; lubricant for heart valves in order to ease placement during surgery; lubricant for ultrasonic catheters; and lubricant for other future devices that employ swiftly-moving parts within the body. In addition, the medical lubricants of the present invention can also be used during placement in the body of catheter like tubes such as are used, for example during atherectomy, transmyocardial revascularization, angioplasty and the like. The medical lubricant emulsions facilitate the advancement of the catheter in a blood vessel by lubrication of the contact zone between the catheter and the blood vessel. The medical lubricants of the invention can similarly be used to ease the placement and advancement of medical devices through the catheter to a site of use in the body in addition to lubricating moving parts within the medical device. The inventive medical lubricants can also contain therapeutic agents that are introduced via a catheter into the body to a specific target location. The medical lubricant emulsion can be infused into the body through a catheter or through a medical device that is located inside a guide catheter.

Depending on the application, the medical lubricant optionally includes one or more therapeutic agents such as a genetic material, a non-genetic therapeutic material, or cells.

Examples of therapeutic agents used in accordance with the invention include, but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, urokinase, and PPACK (dextro-phenylalanine-proline-arginine-chloromethylketone); anti-proliferative agents such as enoxaparin, angiopeptin, or

monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid; anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine; antineoplastic/antiproliferative/anti-mirotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors; anesthetic agents such as lidocaine, bupivacaine, and ropivacaine; anti-coagulants such as D-Phe-Pro-Arg-chloromethylketone, an arginine-glycine-aspartic acid (RGD) peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; vascular cell growth promoters such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators of genes encoding vascular cell growth promoter proteins, and translational activators of mRNAs encoding vascular cell growth promoter proteins; vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors of genes encoding vascular cell growth inhibitors, translational repressors of mRNAs encoding vascular cell growth inhibitors, DNA replication inhibitors, vascular cell growth inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.

In embodiments in which the therapeutic agent includes a substantially purified genetic material, useful polynucleotide sequences include, for example, DNA or RNA sequences having a therapeutic effect after being taken up by a cell. Examples of therapeutic polynucleotides include anti-sense DNA and RNA; DNA coding for an anti-sense RNA; or DNA coding for tRNA or rRNA to replace defective or deficient endogenous molecules. The polynucleotides useful in the invention can also code for therapeutic polypeptides. A therapeutic polypeptide is understood to be any substantially purified translation product of a polynucleotide regardless of size, and whether glycosylated or not. Therapeutic polypeptides include, as a primary example, those polypeptides that can compensate for a defective or deficient species in an animal, or those that act through toxic effects to limit or remove harmful cells from the body. In addition, the polypeptides or proteins that can be incorporated into the coating material of the present invention, or whose DNA can be incorporated, include without limitation, angiogenic factors

including acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor and insulin like growth factor; growth factors; cell cycle inhibitors including CD inhibitors; thymidine kinase ("TK") and other agents useful for interfering with cell proliferation, including agents for treating malignancies. Still other useful factors, which can be provided as polypeptides or as DNA encoding these polypeptides, include the family of bone morphogenic proteins ("BMPs") See, for example, U.S. Patent Nos. 5,948,428, 5,658,882 and 5,393,739. The known proteins include BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. Currently preferred BMPs are any of BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7. These dimeric proteins can be provided as homodimers, heterodimers, or combinations thereof, alone or together with other molecules. Alternatively or, in addition, molecules capable of inducing an upstream or downstream effect of a BMP can be provided. Such molecules include any of the "hedgehog" proteins, or the DNAs encoding them.

In other embodiments, one or more of the therapeutic agents include cells. The therapeutic cells can be of human origin (autologous or allogeneic) or from an animal source (xenogeneic). The cells may be genetically engineered if desired to deliver proteins of interest at the site of cell deposition. The medical lubricant is preferably formulated as needed to maintain cell function and viability.

In a preferred embodiment, the medical lubricant is used in conjunction with an atherectomy device and includes a therapeutic agent that inhibits restenosis. In this embodiment, the therapeutic agent inhibits smooth muscle cell proliferation and comprises a therapeutic agent such as paclitaxel.

In another embodiment, the medical lubricant is used in conjunction with a mechanical transmyocardial revascularization procedure, such as described in U.S. Patent Nos. 5,968,059, which is incorporated herein by reference. The medical lubricants of the present invention are used to lubricate the moving parts of the mechanical transmyocardial revascularization device during performance of the procedure. Alternatively, the inventive medical emulsions can be used in conjunction with other transmyocardial and percutaneous myocardial revascularization devices that utilize a variety of different means to introduce myocardial wounds, such as, for example, a laser transmyocardial revascularization device (U.S. Patent Nos. 5,925,033 and 5,885,272), a radiofrequency transmyocardial

- revascularization device (U.S. Patent No. 5,938,632), a cyro transmyocardial revascularization device (U.S. Patent No. 5,993,444) or an electrode percutaneous myocardial revascularization device (PCT patent application No. PCT/US99/04942). Introduction of a medical lubricant of the present invention during a myocardial
- 5 revascularization procedure may be desirable to lubricate movement of the myocardial ablation device through a tubular delivery catheter as well as during placement of the catheter itself into the patient. In this embodiment of the invention, the medical lubricant preferably comprises a therapeutic agent that promotes angiogenesis such as growth factors, vascular endothelial growth factors, and DNA
- 10 that encodes these growth factors.

Experimental Results

Sample Preparation

- Four one-liter lots of 20% olive oil emulsion were prepared, with each 100 mL of emulsion containing: 20.0 g olive oil, 1.2 g egg yolk phospholipid (a
- 15 surfactant), 0.40 g sodium deoxycholate (a bile salt co-surfactant), 0.16 g L-histidine (an amino acid pH buffer), and 0.014 g disodium EDTA (a preservative). 3.0 mEq/L NaOH was also added to adjust pH. The four lots varied only in glycerin content (a cryogenic agent) in the amounts specified in Table 1. Intralipid, a commercially available lipid emulsion for parenteral nutrition, is included in Table 1 for
- 20 comparison. Intralipid 20% contains 20% w/v soybean oil, egg yolk phospholipids, glycerin, sodium hydroxide, and water for injection (WFI).

Table 1

Glycerin Concentration, Osmolality and Zeta Potential

Lot Number	Glycerin Conc., Grams/100 mL	Osmolality, mOsm/kg	Zeta Potential, mv
Intralipid 20%	2.25	350*	-38
HT-049	1.6	280	-46
HT-050	10.0	300	-48
HT-051	20.0	322	-44
HT-052	30.0	346	-40

- 25 *undiluted sample

High glycerin concentrations are expected to elevate osmolality and depress the freezing point. The original formulation was designed with 1.6% glycerin to produce an isotonic product, having about 280-320 mOsm/kg. As osmolality could not be measured directly in higher concentration glycerin samples using the freezing

point depression method, osmolality was measured after a 1:50 dilution in 0.9% saline. This dilution was chosen to represent expected clinical practice. The osmolality of the Intralipid was measured on an undiluted sample.

The Zeta potential or net surface charge is an important determinant of stability in colloidal systems. Zeta was calculated from microelectrophoretic mobility in 5 mM Hepes buffer at pH 8.0 using a laser light scattering detection system (Malvern ZetaSizer). Control (non-frozen) samples were used. As can be seen in Table 1, Zeta potential was most negative at about 10% glycerin concentration.

Visual Inspection

At least three separate bottles from each lot were visually inspected for homogeneity and surface oil. Inspections were performed on initial samples about one week after sterilization and on samples that had been subjected to freeze/thaw and shipping. "Creaming" refers to the rapid floatation (e.g., within an hour) of large, emulsified oil droplets formed either by coalescence or by aggregation of smaller emulsified droplets. In contrast, surface oil ("free oil") droplets are not emulsified. The results of visual inspection are summarized in Table 2. As can be seen in Table 2, Lot HT-050, having 10% glycerin, had no surface oil and no creaming, either initially or after the freeze/thaw cycle.

Table 2

Visual Examination

Lot No.	Initial (non-frozen)	Post Freeze/Thaw (all temperatures)
HT-049	no surface oil; no creaming	no surface oil; rapid formation of cream layer
HT-050	no surface oil; no creaming	no surface oil; no creaming
HT-051	a few oil droplets (≤ 1 mm); no creaming	a few oil droplets (≤ 1 mm); no creaming
HT-052	no surface oil; no creaming	no surface oil; no creaming

Freeze/Thaw and Stress Testing

Measurements of pH and droplet size were performed on triplicate samples from each lot. Test samples were subjected to freeze/thaw and shipping. Control samples were subjected to no freezing, only shipping. Both control and freeze/thaw

samples were subjected to a saline/heat/shear stress test. This test involves a 1:20 dilution in 0.9% saline, followed by heating in a 40 degree C water bath for 5 minutes, and ending with 3 minute high-shear processing by a rotor-stator device (Ultra Turrax, 20,500 rpm) at 40°C. Due to significant deterioration (creaming),
5 freeze/thaw samples from Lot HT-049 (1.6 % glycerin) were not subjected to this test. Some of the data for Intralipid 20% and Lot HT-050 (10% glycerin) are summarized in Table 3.

Table 3 contains the results: pH (before and after freeze/thaw for Lot HT-050); pH after dilution/heat/shear; mean droplet diameter before and after
10 dilution/heat/shear; droplet diameter for which 90% of the droplets have a smaller diameter before and after dilution/heat/shear; droplet diameter for which 100% of the droplets have a smaller diameter before and after dilution/heat/shear; and the percent of droplets having a droplet diameter greater than 1 micrometer before and after dilution/heat/shear.

15 Inspection of Table 3 shows a significant increase in droplet diameter after dilution/heat/shear stress for Intralipid 20%. As previously discussed, freeze/thaw of Intralipid 20% results in phase separation. Lot HT-050 (10% glycerin) in the control (before freeze/thaw) shows a very slight increase in droplet diameter at the 90th percentile and a maximum droplet size of 4.30 micrometers due to
20 dilution/heat/shear. This compares with an Intralipid increase from 0.80 to 1.23 micrometers droplet diameter at the 90th percentile and maximum droplet size of 12.2 micrometers due to dilution/heat/shear. Freeze/thaw had an insignificant effect on droplet size for the Lot HT-050 sample. Freeze/thaw also had no significant change on the effects of dilution/heat/shear on the HT-050 sample after thawing.

Table 3
Effects of Freeze/Thaw and Heat/Shear
on 20% Olive Oil Emulsions

Lot No./ Storage Condition	pH	Heat/ Shear pH	Mean Dia, μm	Heat/ Shear Mean Dia	90% < μm	Heat/ Shear 90% < μm	100% < μm	Heat/ Shear 100% < μm	% <1 μm	Heat/ Shear %<1 μm
Intralipid 20%/Control	7.85	6.70	0.49	0.67	0.80	1.23	3.49	12.2	4.6	13.9
50/Control	8.63	7.42	.040	.042	0.61	0.65	1.51	4.30	0.50	3.4
50/Frozen @ -30°C	8.64	7.54	0.40	0.41	0.61	0.64	1.51	4.30	0.50	2.6

Phase-Contrast Microscopy

The samples were also observed under phase-contrast microscopy. Freeze/thaw samples from HT-049 (1.6% glycerin) showed a very large number of coalesced and aggregated oil droplets. In contrast, all elevated glycerin samples, HT-050 (10% glycerin), HT-051 (20% glycerin), and HT-052 (30% glycerin) had a very uniform, clean appearance with no large droplets. Samples were also observed after the saline/heat/shear stress test. Samples from all olive oil lots looked excellent, while the Intralipid samples showed many large coalesced droplets. These observations are consistent with the drop size distribution data shown in Table 3.

Sample Test Summary

The addition of glycerin at 10% weight/volume appears sufficient to protect the olive oil emulsions from freeze/thaw damage for at least 48 hours, even at minus 30 degrees C. In this respect, no advantages were seen with higher concentrations of glycerin. The presence of elevated glycerin concentration had no significant effect on product appearance, pH, drop size distribution or Zeta potential. In contrast, the 1.6% glycerin sample (ET-049) exhibited severe creaming following freeze/thaw. The complete preservation of emulsion quality during freeze/thaw using only 10% w/v glycerin (e.g., lot #HT-50) was quite surprising and unexpected. Since samples stored at -30°C appear to be frozen solid, glycerin is not acting as a simple antifreeze agent. Cryopreservation must be occurring by an action at the oil-water interface of the dispersed droplets, i.e., in the phospholipid monolayer.

The addition of each 10% of glycerin, after a 50-fold dilution in 0.9% saline, adds about a 20 mOsm/kg increment in osmolality. Thus, even a 30% glycerin

emulsion has a diluted osmolality no higher than undiluted Intralipid 20%. Therefore no toxicity problems are expected in clinical applications.

Utility

The utility of the invention was tested using the Rotoblator system. This system rotates a 135 cm stainless steel drive coil with an attached diamond coated burr over a 0.009 inch diameter stainless steel guide wire at 180,000 rpm. The system in current use is lubricated during startup with a thin film of HYSTRENE on the guide wire and throughout the operation by a continuous infusion of normal saline. This allows for efficient operation for only limited duration, as the lubricant washes away and is not replenished, therefore the performance can start to degrade as the device starts operating. Performance degradation can take the form of loss of speed, heat build-up, guide wire wear, drive coil wear, burr wear and reduced axial mobility.

Optimally, for use with the Rotoblator Advancer/guide wire system, the lubricant should withstand high shear stress at 50°C without emulsion degradation. All emulsion droplets should remain less than 5 micrometers in diameter, even after shear stress associated with use of this device. In addition, a mixture of the emulsion in saline should remain stable after overnight storage at room temperature and be non-toxic.

Wear and Speed Stability Test

Lubricants were tested using the Rotoblator advancer. An advancer having a 1.75 mm burr was passed through a PTFE tube with a 2.2 mm ID which is wrapped over a pair of mandrels to create a fixed "S" shaped path. The guide wire distal end is placed about 2 inches past the burr and the fixture immersed in a 37°C waterbath and run for 5 minutes. The lubricants tested included both normal saline and saline mixed with 20 cc per liter of the olive oil emulsion. The advancer speed was recorded and the wear scars on the guide wire wear measured with a Laser Micrometer. With saline alone, average wear was 0.0048 inch compared with only 0.0001 inch wear for saline with the emulsion added. With saline alone, the average speed change was a decrease of 13877 rpm, compared with an average increase of 79 rpm for saline with the emulsion added. Thus, both guide wire wear and speed stability improved with the emulsion added.

Tortuous Advance Force Test

Another series of tests was performed, similar to the previous study but having a more tortuous path, to simulate the path of a coronary vessel. The burr was advanced and retracted over an "S" shaped bend throughout the 5 minute test. The

- test measured the force required to advance and retract the burr, the advancer speed, and the fluid temperature downstream of the burr in the PTFE tube. With saline alone, the rpm decreased by 13,000 rpm compared with an increase of 800 rpm for saline with emulsion. With saline alone, the peak fluid temperature was 58°C compared with 47.5°C for saline with emulsion. With saline alone, 170 gm of force was required at the peak to advance the device, compared with 120 gm for saline with emulsion. Thus, the emulsion provided improved lubrication over saline alone.

Comparison with Other Lipid Emulsions

- Another study was performed using stainless steel rods with surface speeds and pressures similar to those found in the Rotoblater. A series of emulsions of olive oil and Intralipid was tested for wear resistance and emulsion stability. The average wear scars using Intralipid were 64 millionths of an inch +/- 16, compared to only 5 millionths of an inch +/- 11 for olive oil emulsions. Furthermore, the olive oil emulsion showed insignificant post shear changes in droplet size distribution, the mean droplet diameter remaining about 0.4 micrometers. In distinct contrast, the Intralipid lubricant showed a dramatic degradation in the emulsion, including an increase in maximum droplet diameter to about 10 micrometers, an increase in mean droplet diameter to about 0.8 micrometers, an increase in 90th percentile droplet diameter from about 0.8 micrometers to about 2 micrometers, and a bimodal distribution in droplet diameter, having a second peak at about 2 micrometers.

Oil Emulsions Comparison Tests

- A series of oil emulsion samples was prepared, all containing 20% weight/volume oil, 1.2% egg yolk phospholipid, 0.16% L-histidine (10 mM), and 0.014% disodium EDTA (0.5 mM). Additional excipients in each sample are indicated in Table 4. Emulsions were prepared by ultrasonic processing (Sonics and Materials Inc., 13 mm horn, 200 mL sample volume, and 80% power for 15 minutes at 50% duty cycle). Drop size distribution was determined by laser light scattering (Malvern MasterSizer). Stainless steel wear testing was expressed as a ratio of stainless steel volume lost with a saline control divided by the volume lost with the test emulsion. Higher ratios indicate less steel lost and therefore better lubrication.

Table 4
Olive Oil-in-Water Emulsion is Most
Effective for Lubrication

Prep No.	Oil Phase, 20% w/v	Aqueous Additive % w/v	Sterile pH	Mean Dia, μm	% > 1 μm	Stainless Steel Wear, <u>Saline</u> Emulsion
1	MCT	None	8.14	1.10	18.4	1.09
2	MCT	Glycerin 2.25%	8.25	0.95	16.8	1.56
3	MCT	PEG-400, 5.0%	8.21	0.87	18.8	0.95
4	MCT	Pluronic F68, 1.0%	8.24	0.49	4.2	1.88
10	15% MCT 5% Castor Oil	None	8.11	0.75	18.4	2.53
6	Olive	None	8.20	0.65	13.0	23.71
9	SBO	None	8.25	0.81	25.6	7.12

- 5 As can be seen from inspection of Table 4, there was a dramatic and unexpected advantage with respect to lubrication efficiency using purified olive oil (Croda) as the emulsified lipid phase versus other oils such as MCT (medium chain triglycerides). Other studies (not shown) confirmed the superiority of olive oil.

Co-surfactant Emulsion Stability Test

- 10 In order to be useful as a lubricant emulsion, the injectable product must be stable for several hours after dilution in unbuffered, normal, 0.9% saline solution. Therefore, a series of samples having various aqueous co-surfactants was tested in a 20% olive oil emulsion. The samples included a control having no co-surfactant, PEG-400 added at 5%, Pluronic F68 (nonionic block copolymer) added at 1%,
 15 sodium deoxycholate (a bile salt) added at 0.2%, and Intralipid 20%. The emulsions were diluted 1:20 in 0.9% saline and allowed to stand overnight at room temperature. Emulsion quality was scored by monitoring the formation of large droplets (% > 1 micrometer) using a laser light scattering instrument. In decreasing order of the percentage of droplets having a diameter greater than 1 micrometer, Intralipid had
 20 60%, Pluronic F68 42%, PEG-400 37%, control 25%, and deoxycholate 6%. From

several experiments such as this, we concluded that the use of deoxycholate as a co-surfactant best protects this olive oil emulsion following saline dilution.

Diluted Intralipid Droplet Size Tests

- Intralipid was evaluated for use as a lubricant in a stainless steel wear test.
- 5 Intralipid was evaluated after dilution in Water For Injection (WFI), after dilution 1:20 in saline, and after dilution in saline with heat/shear stress. The initial Intralipid mean droplet diameter after dilution in WFI was 0.44 micrometer, compared with 2.07 after dilution in saline and 0.96 after dilution in saline with heat/shear stress. The initial percentage of droplets greater than 1 micrometer in diameter was 2.6%,
- 10 compared with 42.8% after dilution in saline and 26.1% after dilution in saline with heat/shear stress. While Intralipid is a safe and clinically acceptable intravenous nutrition product, it is not useful as an injectable lubricant because this soybean oil emulsion shows large oil droplets and creaming following saline dilution/heat/shear stress.

Co-surfactant Saline Dilution/Heat/Shear Stress Tests

- The percentage of large (greater than 1 micrometer) droplets, both initially and after saline dilution/heat/stress testing, was measured for emulsions having a series of co-surfactants. Dimyristoylphosphatidylglycerin (DMPG), a charged lipid,
- 20 was added at 0.2%. Poloxamer 331, a lipophilic, non-ionic block copolymer, as added along with DMPG in another sample. Deoxycholate, a bile acid, was added at 0.4%. Poloxamer 331 was added along with deoxycholate in another sample. Intralipid was also tested.

- The DMPG preparation initially had about 37% of droplets with a diameter greater than 1 micrometer, deoxycholate about 14%, poloxamer/deoxycholate and
- 25 Intralipid about 3%, and poloxamer/DMPG about 2%. The failure of DMPG to cause smaller droplet size was unexpected since this lipid enhances the stabilizing electronegative surface charge on dispersed droplets.

- After saline dilution/heat/stress testing, however, DMPG had about 37% of droplets with a diameter greater than 1 micrometer, poloxamer/deoxycholate about
- 30 32%, Intralipid and poloxamer/DMPG about 27% and deoxycholate about 15%. Thus, while some co-surfactants provide a finer initial droplet size distribution than deoxycholate, they provide much less protection against saline dilution/heat/shear stress. From studies such as these, we concluded that sodium deoxycholate is the most preferred co-surfactant.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention.

These corrections do not change the substance of the letter or the opinion reached with regards to patentability of the multi-vitamin S.E.T. compositions. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

What is claimed is:

1. A medical lubricant oil emulsion comprising a mixture of:
an oil;
a surfactant;
a co-surfactant;
a pH buffer;
a therapeutic agent; and
water.
2. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one anti-thrombogenic agent chosen from heparin, heparin derivatives, urokinase and dextro-phenylalanine-proline-arginine chloromethylketone.
3. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one anti-proliferative agent chosen from enoxaprin, angiopeptin, a monoclonal antibody capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid.
4. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one anti-inflammatory agent chosen from dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine.
5. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one antineoplastic/antiproliferative/anti-mitotic agent chosen from paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, and thymidine kinase inhibitors.
6. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one anesthetic agents chosen from lidocaine, bupivacaine, and ropivacaine.

7. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one anti-coagulant chosen from dextro-phenylalanine-proline-arginine chloromethylketone, an arginine-glycine-aspartic acid peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides.

8. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one vascular cell growth promoter chosen from growth factor inhibitors, growth factor receptor antagonists, transcriptional activators of genes encoding vascular cell growth promoter proteins, and translational activators of mRNAs encoding vascular cell growth promoter proteins.

9. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one vascular cell growth inhibitor chosen from growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors of genes encoding vascular cell growth inhibitors, translational repressors of mRNAs encoding vascular cell growth inhibitors, DNA replication inhibitors, vascular cell growth inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, and bifunctional molecules consisting of an antibody, and a cytotoxin.

10. A medical lubricant as recited in Claim 1, wherein said therapeutic agent is selected from the group consisting of cholesterol-lowering agents, vasodilating agents, and agents which interfere with endogenous vasoactive mechanisms.

11. A medical lubricant as recited in Claim 1, wherein said therapeutic agent comprises at least one agent chosen from a substantially purified genetic material, a substantially purified protein, and cells.

12. A medical lubricant as recited in Claim 11, wherein said genetic material comprises at least one polynucleotide chosen from anti-sense DNA, anti-sense RNA, DNA coding for an anti-sense RNA, DNA coding for a tRNA, DNA coding for a rRNA, and DNA coding for a protein.

13. A medical lubricant as recited in Claim 11, wherein said cells are human cells that are of autologous or allogeneic origin.

14. A medical lubricant as recited in Claim 11, wherein said cells are xenogeneic non-human cells.

15. A medical lubricant as recited in Claim 11, wherein said therapeutic agent comprises at least one protein chosen from acidic fibroblast growth factors, basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor, insulin like growth factor, and bone morphogenic proteins.

16. A medical lubricant as recited in Claim 11, wherein said genetic material comprises at least one DNA encoding a protein chosen from acidic fibroblast growth factors, basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor, insulin like growth factor, and bone morphogenic proteins.

17. A method of lubricating an intravascular device comprising:
preparing a patient for a medical procedure;
inserting into the patient a medical device in need of lubrication;
infusing a medical lubricant into the patient during said insertion or during operation of said medical device, said medical lubricant oil emulsion comprising:
olive oil;
an egg yolk phospholipid;
a bile salt;
an amino acid buffer;
a therapeutic agent; and
water.

18. A method according to Claim 17 wherein the medical procedure is atherectomy, the medical device is an intravascular device, capable of differentially removing intravascular deposits from the walls of an artery; and the therapeutic agent comprises a cell proliferation inhibitor that provides an anti-restenosis effect.

19. A method according to Claim 17 wherein the medical procedure is myocardial revascularization, the medical device is a myocardial revascularization device, and the therapeutic agent comprises an agent that promotes angiogenesis.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72279 A3

- (51) International Patent Classification: **A61K 9/107**
- (21) International Application Number: PCT/US01/09405
- (22) International Filing Date: 23 March 2001 (23.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/534,056 24 March 2000 (24.03.2000) US
- (71) Applicants: **BOSTON SCIENTIFIC LIMITED** [IE/BB]; The Corporate Center, Bush Hill, Bay Street, St. Michael (BB). **FRESENIUS KABI AB** [SE/SE]; S-751 74 Uppsala (SE).
- (72) Inventors: **LYONS, Robert, T.**; 27164 Woodbluff Road, Laguna Hills, CA 92653 (US). **DILLARD, David, H.**; 7923-152nd Avenue NE, Redmond, WA 98052 (US). **FIEGGEN, Bruce**; 41 Coventry Road, Wayne, NJ 07470 (US). **RAUKER, Robert, M.**; 23 Dearth Circle, Ashland, MA 01721 (US). **BLUNI, Scott, T.**; 163 Mossman Road, Sudbury, MA 01776 (US).
- (74) Agent: **TULLETT, Rodney, C.**; Christensen O'Connor Johnson & Kindness PLLC, Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
28 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/72279 A3

(54) Title: MEDICAL EMULSION FOR LUBRICATION AND DELIVERY OF DRUGS

(57) Abstract: A medical lubricant suitable for injection into the blood stream of a patient. The lubricant is suitable for use with rotating equipment such as atherectomy drive shafts moving within sheaths and over guide wires and other minimally invasive medical devices introduced into a patient through a catheter like instrument. The lubricant is an oil-in-water emulsion including a surfactant, a co-surfactant, and a pH buffer. The lubricant can further include a cryogenic agent and a pH adjusting agent. One lubricant includes olive oil as an emulsified oil, egg yolk phospholipid as a surfactant, sodium deoxycholate as a co-surfactant, glycerin as a cryogenic agent, L-histidine as a pH buffer, and is pH adjusted using sodium hydroxide. The lubricant can also include a therapeutic agent. The lubricant can withstand freeze/thaw cycles as well as saline dilution, heating, and shear stress without significant creaming, separation, or unacceptable increases in oil droplet size. Compared to saline, the lubricant provides significantly increased lubrication efficiency for rapidly moving parts.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/US 01/09405

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 15152 A (PHARMACIA & UPJOHN AB ;BOSTON SCIENT CORP (US)) 1 April 1999 (1999-04-01) cited in the application the whole document	1-19
A	US 5 968 059 A (ELLIS LOUIS ET AL) 19 October 1999 (1999-10-19) cited in the application column 1, line 44 - line 55 column 5, line 31 - line 34; claims 1,4 -/-	1-19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents.

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

12 November 2001

Date of mailing of the international search report

22/11/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5618 Patentkan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

Inventor's Application No.
PCT/US 01/09405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 93 15736 A (PHARMOS CORP) 19 August 1993 (1993-08-19) page 1, line 5-9 page 3, line 19 -page 4, line 11 page 5, line 27-34 page 6, line 28 -page 7, line 5 page 7, line 17-31 page 8, line 7-9 page 8, line 34 -page 9, line 16 page 9, line 23,24 page 10, line 24-27 page 17, line 30-33 page 18, line 25,26 page 19, line 15-23 page 21, line 20,21 example 1 claims 1,3-7,16,19-22,25,28</p> <p>---</p>	1-19
A	<p>PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05, 30 May 1997 (1997-05-30) & JP 09 025227 A (UNITIKA LTD), 28 January 1997 (1997-01-28) abstract</p> <p>---</p>	1-19
T	<p>TAMIRISA P ET AL: "Institutional experience with Rotaglide solution during rotablation." AMERICAN JOURNAL OF CARDIOLOGY, vol. 86, no. Suppl. 8A, 16 October 2000 (2000-10-16), page 601 XP001031406 Twelfth Annual Symposium on Transcatheter Cardiovascular Therapeutics;Washington, D. C., USA; October 17-22, 2000 ISSN: 0002-9149 abstract</p> <p>-----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/09405

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9915152	A	01-04-1999	US 6054421 A 25-04-2000 EP 1024791 A1 09-08-2000 WO 9915152 A1 01-04-1999 US 6281175 B1 28-08-2001
US 5968059	A	19-10-1999	DE 971757 T1 31-08-2000 EP 0971757 A1 19-01-2000 WO 9839038 A1 11-09-1998 US 6290709 B1 18-09-2001 US 6238406 B1 29-05-2001
WO 9315736	A	19-08-1993	IL 101007 A 14-08-1997 AU 675930 B2 27-02-1997 AU 3721593 A 03-09-1993 CA 2130357 A1 19-08-1993 EP 0626850 A1 07-12-1994 US 5472706 A 05-12-1995 WO 9315736 A1 19-08-1993 US 5750142 A 12-05-1998 ZA 9301143 A 14-09-1993 JP 8506081 T 02-07-1996
JP 09025227	A	28-01-1997	NONE